Dr. Felipe Ridolfi, PhD, MD presents at CROI 2025 session on Pathogenesis of TB/Disease/TB Drug Exposure Relationships

Dr. Felipe Ridolfi, PhD, MD attended the Conference on Retroviruses and Opportunistic Infections (CROI), in San Francisco, California, where he presented his poster entitled: "Isoniazid Exposure Among Patients With Tuberculosis and Diabetes in Brazil"; based on preliminary work/data from his RICC fellowship project.Authors: Felipe Ridolfi, Gustavo Amorim, Brian C Hachey, Cody Staats, Marcelo Cordeiro-Santos, Afrânio L. Kritski, Marina C. Figueiredo, Bruno B. Andrade, Timothy Sterling, Valeria C. Rolla.

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

Open Date (Earliest Submission Date): April 07, 2025Expiration Date: January 08, 2028Funds Available and Anticipated Number of AwardsThe number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.Award BudgetThe combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 in direct costs may be requested in any single year.

Drs. Robert Watson and Kristin Patrick join VTC

The Vanderbilt Tuberculosis Center is fortunate be joined by Drs. Robert "Robbie" Watson and Kristin Patrick. They join us from Texas A&M, bringing with them considerable expertise and stellar labs focused on basic science and macrophage innate immune response is regulated during bacterial infection Here are some details regarding their labs:

Chao Yan, PhD

Chao
Yan
Postdoctoral Research Fellow
Department of Biomedical Informatics